Financing channel feed – Endpoints News

Financing channel feed

With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work

8 years ago

Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca

8 years ago

Peer Review: Eyeing a $350M venture fund, Nextech recruits Third Rock’s Jakob Loven for the team

8 years ago

Google’s GV and allies double down on Forty Seven with their second $75M round

8 years ago

Pfizer, NEA back Cydan II's plans to launch a fresh slate of biotech startups focused on rare genetic diseases

8 years ago

Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD

8 years ago

OptiNose joins the biotech IPO fiesta, raises $120M in upsized offering

8 years ago

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

8 years ago

Bain, RA back InflaRx’s $55M round after early study produces promising results

8 years ago

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

Deerfield commits $50M-plus to translational drug R&D at the Broad

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

Third Rock-backed Allena looks to springboard a $92M IPO off of a failed PhIIb

8 years ago

Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

Rhythm Pharma IPO goes over the top, snags $120M in latest sign the biotech window is wide open

8 years ago

Backed by Big Pharma VCs, Palleon ramps up a new approach to immuno-oncology with a $48M startup round

8 years ago

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

8 years ago

Top scientists and BD execs craft Cullinan, a $150 million R&D portfolio shop focused on cancer

8 years ago

Genzyme vet David Meeker takes helm at stealthy KSQ with $76M and a new map for drug discovery

8 years ago

Next-gen CAR-T, TCR player Autolus gains $80M for clinical trial work

8 years ago

Two young scientists bag $20M to perfect their CRISPR attack on disease-causing bacteria at upstart Eligo

8 years ago

First page Previous page 137 138 139140141 142 143 Next page Last page